EGFR and non-small cell lung carcinoma: This drug received accelerated approval in 2021 for the treatment of patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations based on a non-randomized, open-label, multicohort phase 1/2 study (NCT02716116) that demonstrated significant clinical benefit [182].